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Background
A retrospective chart review of patients seen in the multiple sclerosis (MS) 
specialty clinic at Alfred Taubman Health Care Center of Michigan Medicine 
between January 1st 2020 and February 29th 2020 was performed. Adult
patients with a diagnosis of MS based on the McDonald Criteria were included 
in the study.
Medical records were accessed electronically on the medical-record software 
Epic.  Data was collected from results of diagnostic tests, notes from health 
care providers and denial letters from insurance companies.
Descriptive statistics were calculated using the statistical software IBM SPSS 
statistics. A chi-square test was used to compare categorical data. T-tests were 
used to compare means and a z-score test was used to test for statistically 
significant differences in gender. Alpha was set at 0.05 with a significance level 
of p<0.05 for statistical significance testing.
Methods and Materials
In this study of 350 patients with multiple sclerosis, we found that although the majority benefited from health insurance (99.4%), approximately 1 in 5 experienced difficulty 
accessing disease modifying therapies due to insurance limitations.  We also found that the financial burdens resulting from these insurance restrictions reduced the ability of 
patients with MS to adhere to therapy with 63.9% (46/72) of these patients (12.1% of the total MS population) unable to continue on a DMT at some point during their MS 
course. This data suggests a gap between health insurance needs and current coverage.
Inability to continue on disease modifying therapies for MS due to high copays has been reported previously and continues to serve as a barrier to access. Of the 72 patients 
experiencing financial difficulties, 7.6% (n=6) were unable to continue on their current DMT because their copays were too high, with subjective reports of up to $3000 a month 
in copay requirements. 
This study found that patients who experienced insurance restrictions while pursuing DMTs for MS were more likely to benefit from public insurance in the form of Medicare and 
Medicaid compared to MS patients who did not experience insurance restrictions. 
The high prices of DMTs has forced patients and providers to abandon shared decision making based on patient preferences and clinical data for adherence to step therapy 
requirements enforced by insurance companies. At least 16 of our patients reported an inability to access their desired DMT due to step therapy requirements. 
Insurance policies should eliminate step therapy programs to further increase access to DMTs for patients with MS, while further research is needed to identify the patients that 
would most benefit from low-efficacy vs intermediate efficacy vs high efficacy DMTs.
Discussion
• One in five patients with MS were found to experience difficulty accessing DMTs 
secondary to insurance restrictions, and 12.1% of the MS population were off 
DMT completely at some point during their MS course. 
• Step therapy as a required approach to treatment was the most common barrier 
to desired DMT treatment. 
• Financial barriers to DMT use secondary to insurance restrictions experienced 
by patients with MS should be further elucidated and alleviated by both 
insurance and drug companies.
Conclusions
Financial limitations and insurance restrictions are frequently cited barriers to 
both starting and transitioning between DMTs1. These factors influence the 
approach to selecting a DMT by both patients and providers2.
The choice of DMT for MS treatment is influenced by Individual patient and 
drug-specific factors3. Perceived severity of MS course, patient views and 
preferences about drug tolerably, safety, convenience, efficacy, and insurance 
restrictions are among the factors considered. Patient prognostic profile is also 
used to guide initial DMT selection including demographic, clinical, and 
imaging characteristics that help predict disease severity. Potential predictors 
of severity include male gender, early progressive disability, poor relapse 
recovery, high burden of disease on MRI, or frequent early attacks4.
Access to high-efficacy DMTs is affected by health insurance coverage3. These 
DMTs are often more expensive than injectables with lower-efficacy profiles. 
For this reason, insurance companies have adopted step therapy approaches 
to MS treatment, in which patients are required to fail a cheaper DMT before 
pursuing a more costly, often higher efficacy, DMT. Although this approach is 
seen as cost-effective, there is no data to support a specific sequencing 
schema for MS treatment. This practice has continued largely due to the 
growing costs of MS treatment, irrespective of the growing number of approved 
DMTs. It has been reported that DMTs increase in price above the level of 
inflation after entering the US market5-7. This is contrary to other drug 
categories that decrease in price after entering a competitive drug market. 
These trends in DMT prices continue to drive healthcare costs among persons 
with multiple sclerosis and result in reduced adherence and access to DMTs7.
Results
Study Aim
This study aims to evaluate the financial limitations and insurance restrictions 
experienced by patients pursuing disease modifying therapy for multiple 
sclerosis and how the approach to choosing treatment for MS is affected.
460 patients were evaluated in the study of which 350 (76.1%) carried a diagnosis 
of MS.  Of these patients, 72 (20.6%) were unable to start or continue their desired 
DMT, as agreed upon by the provider and patient, at some point during their 
treatment course due to financial limitations related to their insurance coverage. 
The most common limitation was a required step therapy approach to treatment, 
followed by lost or reduced insurance coverage, and high copays among others.  
DMTs found to be difficult to access financially were glatiramer acetate (17.7%), 
dimethyl fumarate (17.7%), ocrelizumab (15.2%), beta-interferon-1a (12.7%), 
natalizumab (11.4%), teriflunomide (7.6%), rituximab (6.3%), fingolimod (6.3%), 
beta-interferon-1b (2.5%) and alemtuzumab (2.5%). Tecfidera and beta-interferon-
1a were the DMTs most likely to be discontinued secondary to high copays. 
Ocrelizumab was the most likely DMT to be rejected by insurance due to a 
required step therapy approach to treatment, followed by dimethyl fumarate, 
natalizumab, fingolimod, alemtuzumab, and teriflunomide. Patients experienced 
most of these insurance difficulties at the initiation of treatment with DMTs (65.8%). 
Due to lack of insurance coverage, 46 (12.1%) patients were off DMT at some 
point during their MS. 
The results of this study should be analyzed within the context of the following 
limitations. 
• Patients who experienced insurance restrictions while pursuing disease 
modifying therapies for MS were identified via notes from health care providers 
and insurance denial letters scanned into their medical records.  Given that 
some insurance denial letters may not have been incorporated into a patient’s 
medical record or a health care provider may have excluded financial barriers to 
access to disease modifying therapies, this study may have underestimated the 
number of patients who experienced insurance restrictions in their pursuit of MS 
treatment.  
• Given that only 150 of the 350 MS patients evaluated in this study received all 
of their MS treatment at Michigan Medicine, the remaining 200 patients may 
have experienced financial difficulties accessing disease modifying therapies 
that were not reported in their medical record prior to transferring their care, 
further underestimating the true impact of financial barriers on access to 
disease modifying therapies. 
• Further, the use of free or discounted drug programs that help mitigate out-of-
pocket drug expenses was infrequently reported in patient medical records and 
may have underestimated the number of patients experiencing financial 
difficulties. 
• These limitations along with the retrospective study design may have resulted in 
misclassification bias.
Limitations
